Search

Additional file 1: Figure S1. Correlation between SLIT2 methylation density detected by BSP and SLIT2 methylation level detected by RT-qMSP.

Additional file 12. Confirmation of BP1 overexpression after BP1 transfection in K562 cells detected by western blot (original figure).

Additional file 1: Clinic-pathologic characteristics of AML patients in our research cohort and Cox regression univariate and multivariate analysis of variables for leukemia free survival in AML patients in TCGA dataset.

Additional file 3: Table S3. lncRNA expression analyzed by RNA-seq in K562 cell after BP1 overexpression (original data).

Xi-xi Li,1,2,* Jing-dong Zhou,1,3,4,* Xiang-mei Wen,3,5,* Ting-juan Zhang,1,3,4 De-hong Wu,6 Zhao-qun Deng,3,5 Zhi-hui Zhang,1,3,4 Xin-yue Lian,1,3,4 Pin-fang He,1,3,4 Xin-yu Yao,7 Jiang Lin,3,5 Jun Qian1,3,4*These authors contributed equally to this work1Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China; 2Department of Hematology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu, People’s Republic of China; 3Zhenjiang Clinical Research Center of Hematology, Zhenjiang, Jiangsu, People’s Republic of China; 4The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China; 5Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China; 6Department of Hematology, The Third People’s Hospital of KunShan City, 215300 Kunshan, People’s Republic of China; 7School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of ChinaBackground:Altered expression of the BCL-2 family member MCL-1 has been linked to the progression and outcome of various malignancies. Recently, MCL-1 inhibitor S63845 was reported to kill MCL-1-dependent cancer cells and has potential value in clinical application.Purpose: Herein, we reported MCL-1 expression pattern in Chinese de novo acute myeloid leukemia (AML) and its impact on prognosis and may provide theoretical basis for AML patients using MCL-1 inhibitor in clinics. Real-time quantitative PCR was carried out to detect the transcript of MCL-1 in AML patients.Results: MCL-1 expression was significantly up-regulated in AML compared with controls (P=0.042). We divided the patients into two groups (higher and lower expression of MCL-1) based on the median level. Among both non-acute promyelocytic leukemia (APL) and cytogenetically normal AML (CN-AML), patients with higher expression of MCL-1 correlated with lower complete remission (CR) rate (P=0.031 and 0.004, respectively) and shorter overall survival (OS) time (P=0.008 and 0.004, respectively) compared with those with lower expression of MCL-1. Meanwhile, Cox regression analyses revealed that overexpression of MCL-1 acted as an independent risk factor for OS in non-APL patients and CN-AML patients (P=0.011 and 0.045, respectively). In follow-up patients, MCL-1 expression level decreased after CR compared with newly diagnosis time (P=0.020) and increased after relapse (P=0.004).Conclusion: Our findings suggest that higher expression of MCL-1 predicts poor prognosis and can be used for disease monitoring.Keywords: MCL-1, expression, prognosis, recurrence, acute myeliod leukemia

Additional file 1: Table S1. Clinic-pathologic characteristics of AML in our research cohort.

Additional file 1. Primers used for MethylTarget sequencing, qPCR and qMSP.

Additional file 2. The impact of obesity-related genes expression on leukemia-free survival among AML patients from TCGA databases.

Clinic-pathologic characteristics in AML from our cohort. (DOCX 19 kb)

Additional file 1. This file contains Additional Figures (Figures S1â S2) and Additional Tables (Tables S1â S3). It also includes Additional Methods information and R code for regenerating the LSC17 score.

Lan Yang,1,2,* Jing-Dong Zhou,2,3,* Ting-Juan Zhang,2,3 Ji-Chun Ma,1,2 Gao-Fei Xiao,1,2 Qin Chen,1,2 Zhao-Qun Deng,1,2 Jiang Lin,1,2 Jun Qian,2,3 Dong-Ming Yao1,2 1Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China; 2The Key Laboratory of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China; 3Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China *These authors contributed equally to this work Background and purpose: Abundant studies have shown that lncRNA PANDAR plays an oncogenic role in human solid tumors. Although abnormal expression of PANDAR has been well investigated in solid tumors, it was rarely studied in hematologic diseases. Hence, the aim of this study was to determine the PANDAR expression level and its clinical significance in patients with acute myeloid leukemia (AML).Materials and methods: For detecting the expression level of PANDAR in 119 AML patients and 26 controls, real-time quantitative PCR was used in this study. The prognostic values were evaluated by using Kaplan–Meier analysis, Cox regression analyses, and logistic regression analysis.Results: PANDAR was significantly overexpressed in AML and might be a promising biomarker which could distinguish AML from normal samples (P

Additional file 1: Table S1. The primer sequences for miR-200s clusters.

Figure S1. The prognostic value of SOX genes methylation for OS and LFS among whole-cohort AML patients from TCGA databases. SOX genes methylation (HM450) data was downloaded via cBioPortal ( http://www.cbioportal.org ). AML patients were divided into two groups by the median methylation level of each gene respectively. Figure S2. ROC curve analysis of SOX30 methylation for discriminating AML patients form controls. Table S1. Univariate and multivariate analyses of prognostic factors for overall survival in AML patients. Table S2. Univariate and multivariate analyses of prognostic factors for overall survival in non-M3 AML patients. Table S3. Univariate and multivariate analyses of prognostic factors for overall survival in CN-AML patients. Table S4. Univariate and multivariate analyses of prognostic factors for overall survival and leukemia free survival in MDS patients. (DOCX 660Â kb)

Figure S1. ROC curve analysis using H19 expression for discriminating AML patients from controls. (DOCX 126 kb)

Table S1. Primers used for RQ-PCR, RQ-MSP, and BSP. (DOCX 16 kb)